Skip to main content

Table 3 Adverse events

From: IMRT and carbon ion boost for malignant salivary gland tumors: interim analysis of the COSMIC trial

  

R2: visible residual tumor

 

R1: R1/ Pn + resected tumors

 
  

end of RT

1st f/u

end of RT

1st f/u

Mucositis

I

3 (18.8%)

1 (6.3%)

4 (30.8%)

0

 

II

7 (43.8%)

0

6 (46.2%)

0

 

III

4 (25%)

0

2 (15.4%)

0

Dermatitis

I

13 (81.3%)

0

12 (92.3%)

1 (7.7%)

 

II

2 (12.5%)

0

0

0

 

III

1 (6.3%)

0

1 (7.7%)

0

Xerostomia

I

7 (43.8%)

10 (62.5%)

6 (46.2%)

11 (84.6%)

 

II

0

2 (12.5%)

2 (15.4%)

0

Dysphagia

I

7 (43.8%)

2 (12.5%)

4 (30.8%)

0

 

II

0

0

2 (15.4%)

0

 

III

0

0

0

0

Weight loss

yes

13 (81.3%)

3 (18.8%)

9 (69.2%)

4 (30.8%)

kg

median

5

 

5,5

 
 

min

3

 

5

 
 

max

10

 

12

 

Feeding tube

0

0

0

0

Loss of taste

 

16 (100%)

0

11 (84.6%)

0

Middle ear effusion

6 (37.5%)

5 (31.3%)

2 (15.4%)

2 (15.4%)

Otitis

 

0

0

0

0

Paralysis of facial nerve

1 (6.3%)

1 (6.3%)

1 (7.7%)

1 (7.7%)

Ptosis

 

1 (6.3%)

1 (6.3%)

0

0

Reduced jaw opening

2 (12.5%)

2 (12.5%)

1 (7.7%)

1 (7.7%)

Xerophthalmia

0

1 (6.3%)

1 (7.7%)

0

Conjunctivitis

1 (6.3%)

0

0

0

Lymph edema

1 (6.3%)

1 (6.3%)

0

2 (15.4%)

Hearing impairment

2 (12.5%)

0

0

0